药物性中性粒细胞减少症：聚焦利妥昔单抗诱导的迟发性中性粒细胞减少症
Drug-Induced Neutropenia: A Focus on Rituximab-Induced Late-Onset Neutropenia.
作者信息
Moore Donald C
出版信息
P T. 2016 Dec;41(12):765-768.
Abstract
Rituximab can cause late-onset neutropenia that may result in serious life-threatening complications. The author describes the pathophysiology, incidence, and management of this adverse reaction and presents two case histories.
摘要
利妥昔单抗可导致迟发性中性粒细胞减少症，这可能会引发严重的危及生命的并发症。作者描述了这种不良反应的病理生理学、发生率及处理方法，并呈现了两个病例史。
相似文献
1
Drug-Induced Neutropenia: A Focus on Rituximab-Induced Late-Onset Neutropenia.
P T. 2016 Dec;41(12):765-768.
2
Incidence of late onset neutropenia associated with rituximab use in B cell lymphoma patients undergoing autologous stem cell transplantation.
J Oncol Pharm Pract. 2018 Jul;24(5):323-331. doi: 10.1177/1078155217702214. Epub 2017 Mar 30.
3
Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma.
Clin Lymphoma Myeloma Leuk. 2015 Dec;15(12):761-5. doi: 10.1016/j.clml.2015.07.635. Epub 2015 Aug 6.
4
Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections.
Arthritis Rheum. 2011 Aug;63(8):2209-14. doi: 10.1002/art.30427.
5
Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry.
RMD Open. 2015 Jun 30;1(1):e000034. doi: 10.1136/rmdopen-2014-000034. eCollection 2015.
6
Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature.
Clin Rheumatol. 2016 Oct;35(10):2457-62. doi: 10.1007/s10067-016-3313-y. Epub 2016 May 21.
7
Neutropenia after rituximab treatment: new insights on a late complication.
Curr Opin Hematol. 2012 Jan;19(1):32-8. doi: 10.1097/MOH.0b013e32834da987.
8
Rituximab-related late-onset neutropenia in patients with rheumatic diseases: successful re-challenge of the treatment.
Am J Case Rep. 2015 Apr 9;16:211-4. doi: 10.12659/AJCR.892541.
9
Rituximab-Related Late-Onset Neutropenia in Kidney Transplant Recipients Treated for Antibody-Mediated Acute Rejection.
Exp Clin Transplant. 2017 Aug;15(4):414-419. doi: 10.6002/ect.2016.0027. Epub 2016 Oct 31.
10
Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder.
Mult Scler. 2018 Oct;24(12):1645-1647. doi: 10.1177/1352458518765677. Epub 2018 May 9.
引用本文的文献
1
Neutrophils unveiled in chronic lymphocytic leukemia.
Front Immunol. 2025 Aug 20;16:1609754. doi: 10.3389/fimmu.2025.1609754. eCollection 2025.
2
Differences in the count of blood cells pre-and post-chemotherapy in patients with cancer: a retrospective study (2022).
Front Med (Lausanne). 2025 Apr 16;12:1485676. doi: 10.3389/fmed.2025.1485676. eCollection 2025.
3
Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series.
Front Neurol. 2024 Jun 18;15:1386527. doi: 10.3389/fneur.2024.1386527. eCollection 2024.
4
Neutropenia in Childhood-A Narrative Review and Practical Diagnostic Approach.
Hematol Rep. 2024 Jun 16;16(2):375-389. doi: 10.3390/hematolrep16020038.
5
An update on the incidence, risk factors and mechanisms of rituximab-associated neutropenia.
Arch Med Sci. 2022 Sep 15;20(2):494-505. doi: 10.5114/aoms/152174. eCollection 2024.
6
Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice.
Front Immunol. 2024 Apr 16;15:1351739. doi: 10.3389/fimmu.2024.1351739. eCollection 2024.
7
A Case of Late-Onset Neutropenia in Relapsing-Remitting Multiple Sclerosis Following Ocrelizumab Therapy.
Cureus. 2024 Jan 5;16(1):e51729. doi: 10.7759/cureus.51729. eCollection 2024 Jan.
8
Rituximab and pregnancy: Late-onset neutropenia in a 2-month infant whose mother received rituximab 2 weeks prior to childbirth.
Mult Scler. 2024 Feb;30(2):272-274. doi: 10.1177/13524585231214219. Epub 2023 Nov 24.
9
Microbiological and hematological aspects of canine pyometra and associated risk factors.
Heliyon. 2023 Nov 17;9(12):e22368. doi: 10.1016/j.heliyon.2023.e22368. eCollection 2023 Dec.
10
Optimal use of granulocyte colony-stimulating factor prophylaxis to improve survival in cancer patients receiving treatment : An expert view.
Wien Klin Wochenschr. 2024 Jun;136(11-12):362-368. doi: 10.1007/s00508-023-02300-6. Epub 2023 Nov 27.
本文引用的文献
1
Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry.
RMD Open. 2015 Jun 30;1(1):e000034. doi: 10.1136/rmdopen-2014-000034. eCollection 2015.
2
Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma.
Hematology. 2015 May;20(4):196-202. doi: 10.1179/1607845414Y.0000000188. Epub 2014 Aug 17.
3
Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms.
Expert Rev Hematol. 2011 Dec;4(6):619-25. doi: 10.1586/ehm.11.62.
4
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.
Clin Infect Dis. 2011 Feb 15;52(4):e56-93. doi: 10.1093/cid/cir073.
5
Neutropenia associated with rituximab therapy.
Curr Opin Hematol. 2011 Jan;18(1):49-54. doi: 10.1097/MOH.0b013e3283414edf.
6
Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature.
Medicine (Baltimore). 2010 Sep;89(5):308-318. doi: 10.1097/MD.0b013e3181f2caef.
7
Rituximab-associated neutropenia.
Semin Hematol. 2010 Apr;47(2):180-6. doi: 10.1053/j.seminhematol.2010.01.009.
8
Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.
J Clin Oncol. 2010 Jan 10;28(2):279-84. doi: 10.1200/JCO.2009.25.0274. Epub 2009 Nov 23.
9
Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab.
Intern Med. 2009;48(1):57-60. doi: 10.2169/internalmedicine.48.1368. Epub 2009 Jan 1.
10
Systematic review: agranulocytosis induced by nonchemotherapy drugs.
Ann Intern Med. 2007 May 1;146(9):657-65. doi: 10.7326/0003-4819-146-9-200705010-00009.
Zotero 插件